 Shares of Wave Life Sciences Ltd. jumped about 17 in premarket trading on Tuesday after the company announced a four-year strategic collaboration with GlaxoSmithKline to develop oligonucleotide therapeutics. Wave is already testing WVE-006, an experimental oligonucleotide treatment, for alpha-1 antitrypsin deficiency, a genetic disease that causes liver and lung disease, in preclinical research. GSK will ... The post Wave, GSK enter strategic collaboration that could be worth up to 3.3 billion... 